• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利：CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法，用中文像聊天一样搜索，搜遍4000万医学文献。AI智能推荐，让科研检索更轻松。

立即免费搜索

文件翻译

保留排版，准确专业，支持PDF/Word/PPT等文件格式，支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述，25分钟生成高质量综述，智能提取关键信息，辅助科研写作。

立即免费体验

Editorial: Advances in pharmacotherapy for alcohol use disorder: from mechanisms to clinical interventions.

作者信息

Mangieri Regina A, Sirohi Sunil, Marron Fernandez de Velasco Ezequiel, Kang Seungwoo

机构信息

Division of Pharmacology and Toxicology, College of Pharmacy, The University of Texas at Austin, Austin, TX, United States.

Laboratory of Endocrine and Neuropsychiatric Disorders, Division of Basic Pharmaceutical Sciences, College of Pharmacy, Xavier University of Louisiana, New Orleans, LA, United States.

出版信息

Front Pharmacol. 2025 Aug 15;16:1671114. doi: 10.3389/fphar.2025.1671114. eCollection 2025.

DOI:10.3389/fphar.2025.1671114
PMID:40894199
原文链接:https://pmc.ncbi.nlm.nih.gov/articles/PMC12394971/
Abstract
摘要

相似文献

1
Editorial: Advances in pharmacotherapy for alcohol use disorder: from mechanisms to clinical interventions.社论：酒精使用障碍药物治疗的进展：从机制到临床干预
Front Pharmacol. 2025 Aug 15;16:1671114. doi: 10.3389/fphar.2025.1671114. eCollection 2025.
2
Glucagon-like peptide-1 receptor agonists and alcohol use disorders: An emerging unexpected beneficial effect.胰高血糖素样肽-1受体激动剂与酒精使用障碍：一种新出现的意外有益作用。
Diabetes Obes Metab. 2025 Aug;27(8):4083-4091. doi: 10.1111/dom.16453. Epub 2025 May 13.
3
The Role of Glucagon-Like Peptide-1 Receptor Agonists in the Treatment of Alcohol Use Disorder: Current Evidence and Future Directions.胰高血糖素样肽-1受体激动剂在酒精使用障碍治疗中的作用：当前证据与未来方向
J Clin Psychopharmacol. 2025;45(4):372-375. doi: 10.1097/JCP.0000000000002010. Epub 2025 Apr 7.
4
IUPHAR review - Glucagon-like peptide-1 (GLP-1) and substance use disorders: An emerging pharmacotherapeutic target.IUPHAR 评论——胰高血糖素样肽-1（GLP-1）与物质使用障碍：一个新兴的药物治疗靶点。
Pharmacol Res. 2024 Sep;207:107312. doi: 10.1016/j.phrs.2024.107312. Epub 2024 Jul 18.
5
Effect of the GLP-1 receptor agonist exenatide on pro-inflammatory and metabolic biomarkers in individuals with alcohol use disorder: Post hoc results from a randomized, double-blinded, placebo-controlled clinical trial.胰高血糖素样肽-1受体激动剂艾塞那肽对酒精使用障碍个体促炎和代谢生物标志物的影响：一项随机、双盲、安慰剂对照临床试验的事后分析结果
Alcohol Clin Exp Res (Hoboken). 2025 Aug;49(8):1659-1666. doi: 10.1111/acer.70110. Epub 2025 Jul 9.
6
Glucagon-like Peptide-1 Receptor Agonists: A New Frontier in Treating Alcohol Use Disorder.胰高血糖素样肽-1受体激动剂：治疗酒精使用障碍的新前沿。
Brain Sci. 2025 Jun 29;15(7):702. doi: 10.3390/brainsci15070702.
7
The glucagon-like peptide-1 system is modulated by acute and chronic alcohol exposure: Findings from human laboratory experiments and a post-mortem brain study.胰高血糖素样肽-1 系统受急性和慢性酒精暴露的调节：来自人体实验室实验和死后大脑研究的结果。
Addict Biol. 2022 Sep;27(5):e13211. doi: 10.1111/adb.13211.
8
Interventions for tobacco use cessation in people in treatment for or recovery from substance use disorders.针对正在接受物质使用障碍治疗或已康复的人群的戒烟干预措施。
Cochrane Database Syst Rev. 2016 Nov 23;11(11):CD010274. doi: 10.1002/14651858.CD010274.pub2.
9
Pharmacotherapy for anxiety and comorbid alcohol use disorders.焦虑症合并酒精使用障碍的药物治疗
Cochrane Database Syst Rev. 2015 Jan 20;1(1):CD007505. doi: 10.1002/14651858.CD007505.pub2.
10
Combined pharmacological and psychosocial interventions for alcohol use disorder.酒精使用障碍的药物与心理社会综合干预措施
Cochrane Database Syst Rev. 2025 Mar 20;3(3):CD015673. doi: 10.1002/14651858.CD015673.pub2.

本文引用的文献

1
Glucagon-like peptide-1 receptor agonists, but not dipeptidyl peptidase-4 inhibitors, reduce alcohol intake.胰高血糖素样肽-1受体激动剂可减少酒精摄入量，但二肽基肽酶-4抑制剂则不能。
J Clin Invest. 2025 Mar 6;135(9). doi: 10.1172/JCI188314. eCollection 2025 May 1.
2
Once-Weekly Semaglutide in Adults With Alcohol Use Disorder: A Randomized Clinical Trial.每周一次司美格鲁肽治疗酒精使用障碍成人患者：一项随机临床试验。
JAMA Psychiatry. 2025 Apr 1;82(4):395-405. doi: 10.1001/jamapsychiatry.2024.4789.
3
The benefits of GLP-1 drugs beyond obesity.胰高血糖素样肽-1（GLP-1）药物在治疗肥胖症之外的益处。
Science. 2024 Jul 19;385(6706):258-260. doi: 10.1126/science.adn4128. Epub 2024 Jul 18.
4
A Complex Interplay between Nutrition and Alcohol use Disorder: Implications for Breaking the Vicious Cycle.营养与酒精使用障碍之间的复杂相互作用：对打破恶性循环的启示。
Curr Pharm Des. 2024;30(23):1822-1837. doi: 10.2174/0113816128292367240510111746.
5
Understanding low treatment seeking rates for alcohol use disorder: A narrative review of the literature and opportunities for improvement.理解酒精使用障碍治疗寻求率低的问题：文献回顾与改进机会的叙述性评论。
Am J Drug Alcohol Abuse. 2021 Nov 2;47(6):664-679. doi: 10.1080/00952990.2021.1969658. Epub 2021 Aug 31.
6
Long-Acting Glucagon-Like Peptide-1 Receptor Agonists Suppress Voluntary Alcohol Intake in Male Wistar Rats.长效胰高血糖素样肽-1受体激动剂抑制雄性Wistar大鼠的自愿酒精摄入。
Front Neurosci. 2020 Dec 23;14:599646. doi: 10.3389/fnins.2020.599646. eCollection 2020.
7
Habitual Alcohol Seeking: Neural Bases and Possible Relations to Alcohol Use Disorders.习惯性酒精寻求：神经基础及其与酒精使用障碍的可能关系。
Alcohol Clin Exp Res. 2016 Jul;40(7):1380-9. doi: 10.1111/acer.13094. Epub 2016 May 25.